Search Results
Your search for ,OUr matches 10724 pages
Showing 2751 - 2800Lynn M. Schuchter, MD, FASCO, Elected ASCO President for 2023–2024 Term
ASCO has elected Lynn M. Schuchter, MD, FASCO, a long-time member and volunteer, to serve as its President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the ASCO Annual Meeting in Chicago in June 2022. Seven new members were also elected to the ASCO...
NCCN Guidelines for Prostate Cancer: Panel Clarifies Role of Active Surveillance for Low-Risk Prostate Cancer
In October 2021, the National Comprehensive Cancer Network (NCCN) prostate caycer panel modified its guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines®]) for low-risk prostate cancer to remove the word “preferred option” for active surveillance, giving equal weight to...
Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
Solving the Conundrum of Young-Onset Colorectal Cancer
Although research so far has failed to uncover the root causes of the development of young-onset colorectal cancer, what is certain is that although colorectal cancer rates are declining in older adults, they are on a steady rise in people younger than age 50, especially those between the ages of...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
Colorectal Cancer Screening: Preferences of Gastroenterologists and Primary Care Clinicians
Despite the availability of several effective screening tests, colorectal cancer screening rates remain below national goals. Although colonoscopy is the most often recommended screening method, a new study has found that the preferences of primary care clinicians have shifted toward noninvasive...
Study Examines Possible Clinical Trial Bias From Undisclosed Censoring
New research published by Wilson et al in JNCCN–Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical trials studied provided adequately defined rules for censoring. The researchers examined published randomized control trials supporting U.S. Food and Drug...
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab for Younger Patients With CLL
A study presented by Matthew S. Davids, MD, of Dana-Farber Cancer Institute, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 640) suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy may provide deep and lasting...
HHS Secretary Becerra Names Lawrence Tabak, DDS, PhD, Acting Director of NIH
Health and Human Services Secretary Xavier Becerra recently announced that Lawrence A. Tabak, DDS, PhD, Principal Deputy Director of the National Institutes of Health (NIH), will serve as Acting Director of the NIH effective December 20, 2021. Earlier this year, current NIH Director Francis S....
Study Identifies Factors for Severe COVID-19 Illness Among Patients With Acute Leukemia or MDS
In separate analyses of 257 patients with acute leukemia or myelodysplastic syndrome (MDS) who developed COVID-19 and are part of the American Society of Hematology (ASH) RC COVID-19 Registry for Hematology, both neutropenia and having active MDS or leukemia (vs being in remission) were found to...
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to the standard three-drug induction regimen of...
Antibody Response to COVID-19 Vaccination in Patients With Myeloid and Lymphoid Neoplasms
According to a German study by Rotterdam et al presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 218), about 15% of people with blood cancers and other blood disorders had no vaccination-related antibodies after receiving a COVID-19 vaccine....
ASH RC COVID-19 Registry for Hematology: Risk Factors for Hospitalization and Death Among Patients With Hematologic Malignancies Infected With COVID-19
Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH Research Collaborative (RC)...
Ivosidenib/Azacitidine vs Azacitidine Alone in Patients With Newly Diagnosed IDH1-Mutated AML
In the phase III AGILE trial, the combination of ivosidenib and azacitidine was found to be superior in treating newly diagnosed patients with IDH1-mutated acute myeloid leukemia (AML) compared to azacitidine alone in terms of event-free survival, the study’s primary endpoint. The combination also...
TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma
An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significantly improved event-free survival for patients with large B-cell lymphoma that persisted or returned...
Activity of Mosunetuzumab in Pretreated Patients With Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy, according to pivotal results of a phase I/II trial presented at the 2021 American Society of...
Study Reveals Underrepresentation of AYA Hispanic Patients in a Large ALL Clinical Trial
A study of U.S. adolescent and young adult patients with acute lymphoblastic leukemia (ALL) found that Hispanic patients were significantly underrepresented in a large clinical trial compared with the general patient population. The study, presented by Muffly et al at the 2021 American Society of...
Outcomes Among Pediatric and Young Adult Patients With ALL Differ By Race, Ethnicity, and Socioeconomic Status
A study of nearly 25,000 patients with acute lymphoblastic leukemia (ALL) aged up to 30 years old revealed significant gaps in survival rates between White, Hispanic, and Black patients, as well as worse outcomes among those of lower socioeconomic status. Biologic or genetic factors accounted for...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Nagi El Saghir, MD, FACP, Receives the Susan Bulkeley Butler Leadership Excellence Award
On October 29, 2021, Nagi El Saghir, MD, FACP, received the 2019 Susan Bulkeley Butler Leadership Excellence Award: Making Strides in Cancer Prevention. Because of pandemic-related delays, the award was presented at the 10th International Breast Cancer and Nutrition (IBCN) meeting, hosted by...
Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
Following a review of new data and additional analyses of previous data concerning colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) “concluded the evidence is inadequate that low-dose aspirin use reduces colorectal cancer incidence or mortality.”1 Consequently, a draft...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
Erudition and Assessment on the Longest War in the Modern Era
A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...
Last Hug
“Good evening, doc; I wanted to check on you and update you on my mom” read the text message on a late Thursday afternoon. I recognized the sender; it was not uncommon for me to share my cell phone number with patients and their families. Having been a caretaker of my own parents’ medical needs, I...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
Mount Sinai Health System and BronxCare Health System Open Comprehensive Cancer Facility
Mount Sinai Health System, together with BronxCare Health System, recently held a ribbon-cutting to launch BronxCare Mount Sinai Comprehensive Cancer Care—a new, state-of-the-art comprehensive cancer facility in the Bronx. The new spacewill allow both health systems to bring their strengths...
Newer Cancer Therapies Offer Hope but Also May Confer Cardiac Risk
Since many different chemotherapeutic agents have been linked with cardiac adverse events, there is a growing need for strategies for the assessment and mitigation of treatment-induced cardiotoxicity. Moreover, the rapid rise of immunotherapies has added a new dimension to this clinical setting....
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...
Cancer Researcher and Biotech Founder Lewis Cantley, PhD, Joins Dana-Farber
Lewis Cantley, PhD, the cancer researcher best known for his discovery of the PI3K pathway and his groundbreaking work on cancer metabolism, will be joining the Dana-Farber Cancer Institute in February 2022. Dr. Cantley’s move from his current position as Director of the Sandra and Edward Meyer...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
Profiles of Cancer Risk Associated With Immune-Mediated Diseases
In a study reported in JAMA Oncology, He et al found that individuals with immune-mediated diseases were at an increased risk of developing cancer, with organ-specific immune-mediated diseases being more strongly associated with local vs extralocal cancers. Study Details The prospective cohort...
Patients With Hormone Receptor–Positive Breast Cancer and Emergent ESR1 Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Among patients with hormone receptor–positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
PHOEBE Trial: Pyrotinib/Capecitabine vs Lapatinib/Capecitabine for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer
Among previously treated patients with HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib plus capecitabine, according to updated results from the phase III PHOEBE trial presented by Binghe Xu, MD,...
Expert Point of View: Lee Gazourian, MD
In a panel discussion that followed the presentation by Ravi Kalhan, MD, MS, at the Quantitative Imaging Workshop XVIII, Lee Gazourian, MD, of Lahey Hospital & Medical Center, Massachusetts, emphasized the need for a more centralized approach to the management of incidental findings on chest...
Cleveland Clinic Researcher Receives NIH Director’s Pioneer Award
Michaela Gack, PhD, Scientific Director of Cleveland Clinic’s Florida Research and Innovation Center, has received a National Institutes of Health (NIH) Director’s Pioneer Award to support her research toward the development of broad-spectrum antiviral drugs. The grant is part of NIH’s High-Risk,...
Society for Integrative Oncology Focuses on the Science of Living Well With Cancer
Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances intreating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
How Medical Oncology Came to Be
For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab to chemotherapy as...
Researchers Identify Significant Differences in Tumor Characteristics Between Younger and Older Patients With Cancer
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older patients with cancer across several cancer types. Their research, published by Shah et al in Cell Reports, suggests that cancer treatment could...
Molecular Tumor Profiling May Improve Treatment Matching for Patients With Metastatic Breast Cancer
The use of multigene sequencing and SNP array as a therapeutic decision tool improved the outcomes of patients with metastatic breast cancer if the patients carried alterations classified in the I/II tiers of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT), according to...
I-SPY2 Study Finds Tumor Biology Is a More Significant Factor Than Race in Predicting Response to Breast Cancer Treatment
Data analysis from the I-SPY2 clinical trial found that among women with high-risk breast cancer, race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response (pCR) and event-free survival. The study, which is being presented by...
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...
Evaluation of Carfilzomib-Based Induction, Consolidation, and Maintenance Strategies in Newly Diagnosed Multiple Myeloma
In the Italian phase II FORTE trial reported in The Lancet Oncology, Francesca Gay, PhD, and colleagues found that induction therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) produced a higher response rate vs carfilzomib, cyclophosphamide, and dexamethasone (KCd) among patients aged...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances in treating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
Can Antihistamines Influence Response to Immunotherapy?
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines was associated with improved responses to immune checkpoint inhibitors. The preclinical study, published by Li et al in Cancer Cell, demonstrated that the histamine receptor H1 (HRH1) acts...
Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy
In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...
